Pacific Biosciences Of California (PACB) EBT Margin (2010 - 2026)

Pacific Biosciences Of California's EBT Margin history runs 17 years deep, the most recent figure standing at 21.76% for Q1 2026.

• In Q1 2026, EBT Margin rose 112586.0% year-over-year to 21.76%; the TTM figure through Mar 2026 stood at 79.84% (up 35186.0% YoY), while the FY2025 annual figure was 341.28%, down 14030.0% from the prior year.
• EBT Margin was 21.76% for Q1 2026 at Pacific Biosciences Of California, up from 89.97% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 6.85% in Q4 2024 to a low of 1147.62% in Q1 2025.
• Historically, EBT Margin has averaged 231.66% across 5 years, with a median of 151.94% in 2024.
• The sharpest annual moves came in 2025 and 2026: EBT Margin tumbled 94619 bps in 2025, then soared 112586 bps in 2026.
• A 5-year view of EBT Margin shows it stood at 308.5% in 2022, then surged by 54 bps to 141.78% in 2023, then surged by 105 bps to 6.85% in 2024, then sank by 1413 bps to 89.97% in 2025, then soared by 76 bps to 21.76% in 2026.
• The last three EBT Margin figures came in at 21.76% (Q1 2026), 89.97% (Q4 2025), and 97.86% (Q3 2025), per Business Quant data.